ChengDu Sheng Nuo Biotec (stock ticker 688117.SH) plans to be selected in part for the new round of follow-up purchases.

16:20 11/02/2026

Shengnuo Bio (688117.SH) announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., recently participated in the first to eighth batches of the national centralized procurement of drugs. This round of procurement is the first nationwide unified continuation of chemical drugs by the national organization. According to the "National Organized Drug Procurement Agreement Expiration Variety Continuation Procurement Proposed Selection Results Table" (LC-YPJX-2026-1), the company's products Oxiracetam Injection (winner of the seventh batch), Atosiban Acetate Injection (winner of the eighth batch), Somatostatin Injection (winner of the eighth batch), along with the company's newly selected products Thymosin Alpha-1 Injection and Yitibapeptide Injection, have been selected to participate in this new round of continuation procurement.

ChengDu Sheng Nuo Biotec (688117.SH) announced that its wholly-owned subsidiary, ChengDu Sheng Nuo Biotec Pharmaceutical Co., Ltd., recently participated in the national organized procurement of pharmaceutical products from the first to the eighth batches. This round of continued procurement is the first nationwide unified continuation of chemical drugs organized by the state. According to the "National Organized Procurement Drug Agreement Expiration Variety Continuation Procurement Proposed Selection Results Table" (LC-YPJX-2026-1), the company's products Acetic Acid Octreotide Injection (selected in the seventh batch), Acetic Acid Atosiban Injection (selected in the eighth batch), Somatostatin Injection (selected in the eighth batch) along with the company's newly selected products Thymalfasin Injection, and Icidabapetide Injection are all proposed to be selected in this new round of continuation procurement.

On February 11, SHIYUE DAOTIAN (09676) spent HK$4.2497 million to repurchase 486,900 shares.

Shanghai Pharmaceuticals Holding (02607): Zhao Yong elected as employee director

NETEASE MUSIC (09899) announced its performance in 2025, with adjusted net profit of approximately 2.86 billion yuan, a year-on-year increase of 68.2%.

On February 11, SHIYUE DAOTIAN (09676) spent HK$4.2497 million to repurchase 486,900 shares.

Shanghai Pharmaceuticals Holding (02607): Zhao Yong elected as employee director

NETEASE MUSIC (09899) announced its performance in 2025, with adjusted net profit of approximately 2.86 billion yuan, a year-on-year increase of 68.2%.